STAT+: Launch prices for new medicines dipped slightly last year but remain high, analysis finds

The median net price for 202 newly launched medicines rose by 35%, to 257,000 last year from 173,000 in 2022.

By SilvermanOct 20, 2026

Score█████░░░░░4.7

VerdictCompetent work. Briefs at most.

Summary from the source

The median net price for 202 newly launched medicines rose by 35%, to $257,000 last year from $173,000 in 2022.

Ed Silverman

Heuristic review

Leverage2 / 5: Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).; 15% of this desk’s rubric
Magnitude2 / 5: Solid incremental gain on a meaningful problem.; 20% of this desk’s rubric
Evidence2 / 5: Limited: single setting, weak baselines, or an observational association presented as causal.; 20% of this desk’s rubric
Novelty2 / 5: A new combination of known ideas.; 10% of this desk’s rubric
Trajectory2 / 5: Some room to improve with obvious engineering.; 10% of this desk’s rubric
Stakes2 / 5: Benefits a professional community (practitioners, clinicians, engineers).; 25% of this desk’s rubric

Dimension	Level	Weight	What that level means
Leverage	██░░░ 2	15%	Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).
Magnitude	██░░░ 2	20%	Solid incremental gain on a meaningful problem.
Evidence	██░░░ 2	20%	Limited: single setting, weak baselines, or an observational association presented as causal.
Novelty	██░░░ 2	10%	A new combination of known ideas.
Trajectory	██░░░ 2	10%	Some room to improve with obvious engineering.
Stakes	██░░░ 2	25%	Benefits a professional community (practitioners, clinicians, engineers).

Editor’s rationale

Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: verification (error bars).

rank-2026-10-18

Score█████░░░░░4.7

Score = 10 × (50% × adjusted merit / 10 + 25% × attention + 25% × freshness)

Desks place stronger verdicts first, then use this score to order work within the same verdict.

Merit: 3.4 / 10; Weighted rubric, evidence-gated.
Adjusted merit: 3.8 / 10; Shrunk toward the desk prior by editor confidence (30%).
Attention: 28%; Citations, upvotes, points, mentions.
Freshness: 84%; Half-life decay since publication.

No attention signals recorded yet.

Reviewed by heuristic-v7 on Oct 20, 2026, 12:58 UTC. Paper type: news.
Categories: Pharmalot, biotechnology, drug pricing, Pharmaceuticals, Policy, STAT+
TOP, No.7 in the News edition of October 20, 2026.